The true methodology for rhamnolipid: Various solvents affect rhamnolipid characteristics

OUP accepted manuscript

Rhamnolipids (RLs) are well-studied biosurfactants naturally produced by pathogenic strains of Pseudomonas aeruginosa. Current methods to produce RLs in native and heterologous hosts have focused on carbohydrates as production substrate; however, methane (CH₄) provides an intriguing alternative as a substrate for RL production because it is low cost and may mitigate greenhouse gas emissions. Here, we demonstrate RL production from CH₄ by Methylotuvimicrobium alcaliphilum DSM19304. RLs are inhibitory to M. alcaliphilum growth (<0.05 g/l). Adaptive laboratory evolution was performed by growing M. alcaliphilum in increasing concentrations of RLs, producing a strain that grew in the presence of 5 g/l of RLs. Metabolomics and proteomics of the adapted strain grown on CH₄ in the absence of RLs revealed metabolic changes, increase in fatty acid production and secretion, alterations in gluconeogenesis, and increased secretion of lactate and osmolyte products compared with the parent strain. Expression of plasmid-borne RL production genes in the parent M. alcaliphilum strain resulted in cessation of growth and cell death. In contrast, the adapted strain transformed with the RL production genes showed no growth inhibition and produced up to 1 μM of RLs, a 600-fold increase compared with the parent strain, solely from CH₄. This work has promise for developing technologies to produce fatty acid-derived bioproducts, including biosurfactants, from CH₄.

Rhamnolipids from non-pathogenic Acinetobacter calcoaceticus: Bioreactor-scale production, characterization and wound healing potency

Rhamnolipids are predominantly produced from the opportunistic pathogen Pseudomonas aeruginosa, which restricts their scaled-up production and biomedical applications. Moreover, the wound healing property of rhamnolipids is mainly focused on either mono- or di-rhamnolipid congeners, which are obtained after extensive and costly purification procedures. Here, crude rhamnolipids from non-pathogenic Acinetobacter calcoaceticus BU-03 have been prepared and characterized and their wound healing potency evaluated in vitro and in vivo. Rhamnolipid extract was produced in a bioreactor by batch fermentation at a concentration of 12.7 ± 1.4 g/L. Characterization of the extract by Fourier Transform Infrared spectroscopy and mass spectrometry revealed characteristic rhamnolipid peaks. Rha-C10-C10 and Rha-Rha-C10-C10 appeared as the predominant congeners along with minor quantities of six more congeners. The rhamnolipid extract obtained from A. calcoaceticus had no toxicity against mouse fibroblast L929 cells and accelerated their migration. Transforming growth factor beta 1 (TGF-β1) has been shown to promote fibroblast migration by activating Smad3. It was found that the rhamnolipid extract enhanced Smad3 phosphorylation in L929 cells. In vivo studies showed that it promoted wound healing in mice with excisional wounds. The protein levels of TGF-β1 and alpha smooth muscle actin (α-SMA), a highly contractile protein, were significantly increased by 2.56- and 1.51-fold, respectively, in extract-treated compared with vehicle control-treated wounds, indicating that the activation of TGF-β1 signaling is possibly involved in the wound healing effect. These results suggest that a rhamnolipid extract obtained from A. calcoaceticus has potential as a wound healing material for topical application in cutaneous wound treatment.

Microbial biosurfactant research: time to improve the rigour in the reporting of synthesis, functional characterization and process development

The demand for microbially produced surface-active compounds for use in industrial processes and products is increasing. As such, there has been a comparable increase in the number of publications relating to the characterization of novel surface-active compounds: novel producers of already characterized surface-active compounds and production processes for the generation of these compounds. Leading researchers in the field have identified that many of these studies utilize techniques are not precise and accurate enough, so some published conclusions might not be justified. Such studies lacking robust experimental evidence generated by validated techniques and standard operating procedures are detrimental to the field of microbially produced surface-active compound research. In this publication, we have critically reviewed a wide range of techniques utilized in the characterization of surface-active compounds from microbial sources: identification of surface-active compound producing microorganisms and functional testing of resultant surface-active compounds. We have also reviewed the experimental evidence required for process development to take these compounds out of the laboratory and into industrial application. We devised this review as a guide to both researchers and the peer-reviewed process to improve the stringency of future studies and publications within this field of science.

Biosurfactants’ Potential Role in Combating COVID-19 and Similar Future Microbial Threats

During 2020, the world has experienced extreme vulnerability in the face of a disease outbreak. The coronavirus disease 2019 (COVID-19) pandemic discovered in China and rapidly spread across the globe, infecting millions, causing hundreds of thousands of deaths, and severe downturns in the economies of countries worldwide. Biosurfactants can play a significant role in the prevention, control and treatment of diseases caused by these pathogenic agents through various therapeutic, pharmaceutical, environmental and hygiene approaches. Biosurfactants have the potential to inhibit microbial species with virulent intrinsic characteristics capable of developing diseases with high morbidity and mortality, as well as interrupting their spread through environmental and hygiene interventions. This is possible due to their antimicrobial activity, ability to interact with cells forming micelles and to interact with the immune system, and compatibility with relevant processes such as nanoparticle synthesis. They, therefore, can be applied in developing innovative and more effective pharmaceutical, therapeutics, sustainable and friendly environmental management approaches, less toxic formulations, and more efficient cleaning agents. These approaches can be easily integrated into relevant product development pipelines and implemented as measures for combating and managing pandemics. This review examines the potential approaches of biosurfactants as useful molecules in fighting microbial pathogens both known and previously unknown, such as COVID-19.